962 A novel alpha-active IL-2-Fc has expanded therapeutic index and robust monotherapy efficacy in mouse cancer models and strong synergy with PD-1 blockade
Adam Stockmann(TScan Therapeutics (United States)), Ann Cheung(Wave Dragon (Denmark)), Nicolai Wagtmann(Howard Hughes Medical Institute), Jingya Ma(Millennium Engineering and Integration (United States)), Jaafar N. Haidar(Dragonfly Therapeutics (United States)), Sara Basinski(Dragonfly Therapeutics (United States)), S.R. Vincent(Dragonfly Therapeutics (United States)), Asya V. Grinberg(Dragonfly Therapeutics (United States)), Lauren Herschelman(Dragonfly Therapeutics (United States)), Patrick Kirby(TScan Therapeutics (United States)), Dan Fallon(Dragonfly Therapeutics (United States)), Ching-Shin Huang(Pfizer (United States))
Cited by 0
Related Papers
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461
Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors
|Nature|1997|165
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
|Science Advances|2020|95
A Novel Six-Rhodopsin System in a Single Archaeon
|Journal of Bacteriology|2010|54